カテゴリ： GlobalData, インド, 企業調査

Dr. Reddy’s Laboratories Ltd (DRREDDY)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Dr. Reddy's Laboratories Ltd (DRREDDY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9887
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：122
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：インド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Dr. Reddy’s Laboratories Ltd (Dr. Reddy’s) is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company’s generic products are used for the treatment of conditions such as gastrointestinal disorders, oncology, cardiovascular diseases, pain management, Central Nervous System, cancer, pain, infectious diseases and pediatrics. The company provides more than 150 products. The company also develops generic biosimilar products and has four products in the market. The company also discovers, develops, manufactures and markets New Chemical Entities (NCEs) focusing on bacterial infections, metabolic disorders, pain and inflammation. The company markets products in over 75 countries in the US, Europe, Latin America and Asia. Dr. Reddy’s is headquartered in Hyderabad, Telangana, India.

Dr. Reddy’s Laboratories Ltd (DRREDDY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Dr. Reddy’s Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 17
Dr. Reddy’s Labs Acquires Six OTC Brands from Ducere Pharma 19
Dr. Reddy’s Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 20
Dr Reddy’s Labs Acquires Brands Portfolio of UCB for USD128 Million 21
Dr Reddy’s Labs Acquires Habitrol from Novartis Consumer Health 22
Dr Reddy’s Labs Plans To Acquire Drug Brands In Latin America 23
Private Equity 24
Cipla, Zydus Cadilla, Dr. Reddy’s Labs and Baring Asia May Acquire Bharat Serums and Vaccines 24
Partnerships 26
Dr. Reddy’s Laboratories Enters into Distribution Agreement with UCB 26
Department of Science & Technology Enters into Agreement with Dr Reddy’s Labs, University of Hyderabad and Dr Reddy’s Institute of Life Sciences 27
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 28
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 29
CutisPharma Partners with Dr. Reddy’s Labs 30
Dr. Reddy’s Labs Enters into Agreement with TR-Pharm 31
Dr. Reddy’s Labs Enters into Distribution Agreement with Biocodex 32
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen 33
Purdue University Enters into MoU with Dr Reddy’s Labs 34
Dr Reddy’s Labs Enters into Distribution Agreement with Astrazeneca Pharma 35
Dr Reddy’s Labs Plans to Enter into Agreement 36
Aurigene Discovery Enters into Agreement with Curis 37
Shenzhen Foncoo Pharmaceutical Enters into Agreement with Dr. Reddy’s Laboratories 39
Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 40
Licensing Agreements 41
Encore Dermatology Enters into Licensing Agreement with Promius Pharma 41
Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 42
Dr. Reddy’s Labs Enters into Licensing Agreement with Eisai for E7777 43
Dr. Reddy’s Labs Enters into Licensing Agreement with XenoPort for XP23829 44
Curis Exercises Option for Licensing Agreement with Aurigene Discovery 45
Dr. Reddy’s Labs Enters into Licensing Agreement with PanTheryx for DiaResQ 47
Taxus Cardium Pharma Enters into Licensing Agreement with Dr. Reddy’s Labs 48
Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 49
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 50
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 51
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy’s Labs For NeuVax 52
Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 53
Dr. Reddy’s Labs Enters into Agreement with Hatchtech for Xeglyze Lotion 54
Dr Reddy’s Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 55
Promius Pharma Enters into Licensing Agreement with CMP Pharma for Trianex 56
Equity Offering 57
Octoplus Completes First Tranche Of Private Placement Of Common Stock For US$1.6 Million 57
Asset Transactions 58
Therapiva to Acquire API Manufacturing Business Unit from Dr. Reddy’s Laboratories 58
EPI Health Acquires Rights of Cloderm from Promius Pharma 59
Genomma Lab Acquires Bufferin Brand from Dr. Reddy’s Labs 60
Acquisition 61
Neopharma Acquires Dr. Reddy’s Laboratories Tennessee from Dr. Reddy’s Laboratories 61
Dr Reddy’s Labs Acquires OctoPlus 62
Dr. Reddy’s Laboratories Ltd – Key Competitors 64
Dr. Reddy’s Laboratories Ltd – Key Employees 65
Dr. Reddy’s Laboratories Ltd – Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Joint Venture 68
Recent Developments 69
Financial Announcements 69
Oct 26, 2018: Dr. Reddy’s Q2 & H1 FY19 financial results 69
Jul 26, 2018: Dr. Reddy’s Q1 FY19 financial results 70
May 22, 2018: Dr. Reddy’s Q4 and FY18 Financial Results 72
Jan 25, 2018: Dr. Reddy’s Q3 and 9M FY18 Financial Results 74
Oct 31, 2017: Dr. Reddy’s Q2 and H1 FY18 Financial Results 76
Jul 27, 2017: Dr. Reddy’s Q1 FY18 Financial Results 77
May 12, 2017: Dr. Reddy’s Q4 and FY17 Financial Results 78
Feb 04, 2017: Dr. Reddy’s Q3 and 9M FY17 Financial Results 80
Corporate Communications 82
Oct 25, 2018: Dr. Reddy’s Laboratories: Appointment of Mr. Leo Puri as an Additional Director, categorjzed as Independent, on the Board of the Company 82
Jun 14, 2018: Dr. Reddy’s Announces Resignation of Hans Peter Hasler As Independent Director 83
Mar 29, 2018: Dr. Reddy’s Laboratories announces Senior Leadership Changes 84
Oct 30, 2017: Dr Reddys Laboratories appoints Prasad R Menon as an Additional Director 85
Legal and Regulatory 86
Oct 30, 2018: Dr Reddy’s slips 7% following 8 USFDA observations for Duvvada plant 86
Aug 23, 2018: Dr. Reddy’s Laboratories: Update on audit of API Srikakulam Plant, Andhra Pradesh 87
Jun 28, 2018: Dr. Reddy’s Laboratories: Update on Audit of its API Hyderabad Plant 3 and API Hyderabad Plant 1 88
Jun 28, 2018: Indivior’s Temporary Restraining Order is Extended 89
Jun 03, 2018: Dr Reddy’s API Srikakulam plant gets USFDA nod 90
Jun 02, 2018: Dr. Reddy’s Laboratories Provides Update on US FDA Inspection of its API Srikakulam Plant 91
Apr 24, 2018: Dr. Reddy’s Laboratories Provides Update on US FDA Inspection of its API Plant in Mirfield, UK 92
Mar 16, 2018: Dr. Reddy’s Provides Update on Update on USFDA Audit of its API Hyderabad Plant at Medak,Telangana 93
Feb 25, 2018: Dr. Reddy’s Laboratories Provides Update on USFDA Audit of its API Manufacturing Plant at Srikakulam, India 94
Feb 19, 2018: Dr Reddy’s Laboratories: Update on US Lawsuit 95
Jan 24, 2018: Dr. Reddy’s Laboratories: Intimation regard to Communication from Betapharm Arzneimittel, Germany from the Regulatory Authority of Germany 96
Jan 22, 2018: Dr. Reddy’s fined $5mn by US court over drug packaging 97
Dec 19, 2017: Dr. Reddy’s announces it has reached a settlement with the US Government regarding company’s compliance with the Consumer Product Safety Act 98
Dec 11, 2017: Dr. Reddys announced audit of formulations manufacturing plant 99
Dec 01, 2017: Dr. Reddy’s Laboratories: Intimation regard to the US FDA audit 100
Nov 21, 2017: Dr. Reddy’s Laboratories: Intimation regarding receipt of EIR 101
Sep 21, 2017: Dr. Reddys Announced audit of custom Pharmaceutical Services Facility 102
Sep 21, 2017: Dr. Reddy’s Laboratories: Intimation about audit of Srikakulam Plant Unit II, Andhra Pradesh, by the US FDA 103
Sep 15, 2017: Dr. Reddy’s Laboratories: Intimation about audit of API Mirfield Plant, United Kingdom, by the US FDA 104
Sep 08, 2017: Dr. Reddy’s Laboratories: Regulatory Authority of Germany concludes audit of Formulations manufacturing facility in Vishakapatnam, India 105
Sep 08, 2017: Dr. Reddy’s Laboratories Announces Intimation on audit 106
Jul 21, 2017: Dr. Reddy’s Laboratories: Update On US FDA Audit at API Cuernavaca Plant 107
Jun 16, 2017: Dr. Reddy’s Laboratories: Update on USFDA Audit 108
Jun 14, 2017: Dr. Reddy’s Provides Update on API manufacturing plant at Miryalaguda 109
May 25, 2017: Dr. Reddy’s Laboratories Provides Update on Srikakulum Plant 110
Apr 28, 2017: Dr. Reddy’s Provides Update On US FDA Audit At Bachupally Plant 111
Apr 14, 2017: Dr. Reddy’s Provides Update on USFDA Audit 112
Apr 03, 2017: Dr. Reddy’s Laboratories Provides Update on USFDA Inspection at Srikakulam plant 113
Feb 21, 2017: Dr. Reddy’s Laboratories Announces US FDA Inspection on Miryalaguda Facility 114
Product News 115
12/01/2017: Dr. Reddy’s Announces Approval of Impoyz (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval 115
Aug 28, 2017: Dr. Reddy’s Laboratories Breathes New Life into Doan’s in New Marketing Campaign 116
Jun 03, 2018: Dr Reddy’s expects to launch over 15 products in US in FY’19 117
Jan 17, 2018: Dr Reddy’s recalls over 1,000 vials of cancer drug from US 118
Clinical Trials 119
Feb 07, 2018: Armis Biopharma to Present at the BIO CEO & Investor Conference 119
Jan 29, 2018: Armis Biopharma Granted QIDP for Lead Product, Ximycin for Prophylaxis of Surgical Site Infections in High-Risk Patients Undergoing Non-Emergent Colorectal Surgery 120
Other Significant Developments 121
Feb 08, 2017: Dr. Reddy’s Expands Commercial Operations in Europe 121
Appendix 122
Methodology 122
About GlobalData 122
Contact Us 122
Disclaimer 122

List of Tables
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Dr. Reddy's Laboratories Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 17
Dr. Reddy’s Labs Acquires Six OTC Brands from Ducere Pharma 19
Dr. Reddy’s Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 20
Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 21
Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 22
Dr Reddy's Labs Plans To Acquire Drug Brands In Latin America 23
Cipla, Zydus Cadilla, Dr. Reddy’s Labs and Baring Asia May Acquire Bharat Serums and Vaccines 24
Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 26
Department of Science & Technology Enters into Agreement with Dr Reddy’s Labs, University of Hyderabad and Dr Reddy’s Institute of Life Sciences 27
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 28
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 29
CutisPharma Partners with Dr. Reddy's Labs 30
Dr. Reddy's Labs Enters into Agreement with TR-Pharm 31
Dr. Reddy’s Labs Enters into Distribution Agreement with Biocodex 32
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen 33
Purdue University Enters into MoU with Dr Reddy's Labs 34
Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 35
Dr Reddy's Labs Plans to Enter into Agreement 36
Aurigene Discovery Enters into Agreement with Curis 37
Shenzhen Foncoo Pharmaceutical Enters into Agreement with Dr. Reddy's Laboratories 39
Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 40
Encore Dermatology Enters into Licensing Agreement with Promius Pharma 41
Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 42
Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 43
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 44
Curis Exercises Option for Licensing Agreement with Aurigene Discovery 45
Dr. Reddy’s Labs Enters into Licensing Agreement with PanTheryx for DiaResQ 47
Taxus Cardium Pharma Enters into Licensing Agreement with Dr. Reddy's Labs 48
Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 49
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 50
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 51
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 52
Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 53
Dr. Reddy’s Labs Enters into Agreement with Hatchtech for Xeglyze Lotion 54
Dr Reddy's Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 55
Promius Pharma Enters into Licensing Agreement with CMP Pharma for Trianex 56
Octoplus Completes First Tranche Of Private Placement Of Common Stock For US$1.6 Million 57
Therapiva to Acquire API Manufacturing Business Unit from Dr. Reddy's Laboratories 58
EPI Health Acquires Rights of Cloderm from Promius Pharma 59
Genomma Lab Acquires Bufferin Brand from Dr. Reddy’s Labs 60
Neopharma Acquires Dr. Reddy's Laboratories Tennessee from Dr. Reddy's Laboratories 61
Dr Reddy's Labs Acquires OctoPlus 62
Dr. Reddy's Laboratories Ltd, Key Competitors 64
Dr. Reddy's Laboratories Ltd, Key Employees 65
Dr. Reddy's Laboratories Ltd, Subsidiaries 66
Dr. Reddy's Laboratories Ltd, Joint Venture 68

List of Figures
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[Dr. Reddy’s Laboratories Ltd (DRREDDY)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • ConAgra Brands Inc：企業のM&A・事業提携・投資動向
    ConAgra Brands Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ConAgra Brands Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Deckers Outdoor Corporation (DECK)：企業の財務・戦略的SWOT分析
    Deckers Outdoor Corporation (DECK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Franklin Street Properties Corp：企業の戦略・SWOT・財務分析
    Franklin Street Properties Corp - Strategy, SWOT and Corporate Finance Report Summary Franklin Street Properties Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Neuralstem Inc (CUR)-医療機器分野：企業M&A・提携分析
    Summary Neuralstem Inc (Neuralstem) is a developer of medicines for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer’s disease, traumatic brain injury, peripheral nerve injury, diabetic neur …
  • Air Liquide Welding France, S.A.：企業の戦略・SWOT・財務情報
    Air Liquide Welding France, S.A. - Strategy, SWOT and Corporate Finance Report Summary Air Liquide Welding France, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Companhia de Transmissao de Energia Eletrica Paulista (TRPL4)：企業の財務・戦略的SWOT分析
    Summary Companhia de Transmissao de Energia Eletrica Paulista (CTEEP) a subsidiary of Interconexion Electrica SA ESP, is an electric utility service provider that produces and distributes electricity. The utility owns and operates power generation plants and transmission lines and supplies electrici …
  • Stena AB：企業の戦略的SWOT分析
    Stena AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • PTC India Limited (PTC)-エネルギー分野：企業M&A・提携分析
    Summary PTC India Limited (PTC) formerly Power Trading Corporation of India Limited, is a provider of power trading solutions. The company is a public-private partnership entity initiated by the government of India. It carries out trading activities which include, long term trading of power generate …
  • Immunogen, Inc.
    Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • VTT Technical Research Centre of Finland-製薬・医療分野：企業M&A・提携分析
    Summary VTT Technical Research Centre of Finland (VTT) is a research and technology center that offers development services. The center provides research services on bioeconomy and circular economy, health and wellbeing, digital society, low carbon energy, smart industry, sustainable and smart city, …
  • Animalcare Group Plc (ANCR)：企業の財務・戦略的SWOT分析
    Summary Animalcare Group Plc (Animalcare) is a animal healthcare service provider that develops and supplies veterinary medicines and services. The company offers products such as licensed veterinary medicines, companion animal identification and animal welfare products. It offers its product to dog …
  • Celina Insurance Group：企業の戦略・SWOT・財務情報
    Celina Insurance Group - Strategy, SWOT and Corporate Finance Report Summary Celina Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Exide Technologies：企業の戦略・SWOT・財務分析
    Exide Technologies - Strategy, SWOT and Corporate Finance Report Summary Exide Technologies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Innsuites Hospitality Trust：企業の戦略・SWOT・財務分析
    Innsuites Hospitality Trust - Strategy, SWOT and Corporate Finance Report Summary Innsuites Hospitality Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Boise Cascade Co (BCC)：企業の財務・戦略的SWOT分析
    Summary Boise Cascade Co (Boise Cascade) is engaged in the manufacture and distributor of wood products and building materials. The company's product portfolio include engineered wood, panels and lumber and building materials. Its building materials comprise concrete products, adhesive, gypsum, insu …
  • Grupo Nutresa SA (NUTRESA)：企業の財務・戦略的SWOT分析
    Grupo Nutresa SA (NUTRESA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Foodstuffs South Island Ltd：戦略・SWOT・企業財務分析
    Foodstuffs South Island Ltd - Strategy, SWOT and Corporate Finance Report Summary Foodstuffs South Island Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • McWane Inc：企業の戦略的SWOT分析
    McWane Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Invenergy LLC：発電所・企業SWOT分析
    Invenergy LLC - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • CRISPR Therapeutics：戦略・SWOT・企業財務分析
    CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report Summary CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆